This message has been cross posted to the following eGroups: Biopharmaceutical Section and Statistical Consulting Section .
-------------------------------------------
Dear colleagues, The background- I'm a member of both the ASA and "ISPOR" (International Society of Pharmacoeconomics and Outcomes Research
www.ispor.org ).
FYI - Before (cross-) posting here I alerted the section chairs for Biopharm / Statistical Consulting/Biometrics that I am looking for a few volunteers .
I (and others at ISPOR) recently received a request from an ISPOR SIG (special interest group) to review and comment on a "good practices" guideline for assessing prospective observational studies. The document is ultimately intended for use by Health Care Decision makers
I will be providing comments to the ISPOR Sig on the document.
I'd be glad to have input from colleagues at ASA. Please send me an email offline at (
chris.barker@barkerstats.com) if you would have time to review and comment on the document. (I am not posting the document here). I will assemble comments and forward to the ISPOR SIG.
- N.B. All Comments are due on September 20.
thanks in advance.
-------------------------------------------
Chris Barker, Ph.D.
Consultant and
Adjunct Associate Professor of Biostatistics
www,barkerstats.com
---
"In composition you have all the time you want to decide what to say in 15 seconds, in improvisation you have 15 seconds."
-Steve Lacy
-------------------------------------------